Related Experiment Video
Updated: Jul 12, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Current status of iron overload and chelation with deferasirox
1Department of Hematology, All India Institute of Medical Sciences, New Delhi, India. vedpchoudhry@yahoo.co.in
Abstract:
A large number of complications in thalassemia major are due mainly to iron overload. Deferoxamine in iron-overloaded patients has established that chelation therapy, when given at an adequate dose, reduces iron-related complications. Parenteral administration and the daily nuisance of an infusion pump hinder the optimal compliance. Deferiprone is moderately effective oral iron chelator. Arthralgia and cytopenias constitute the main side effects. Deferasirox is a new orally effective iron chelator which has been shown to be non-inferior to deferoxamine in clinical trials. Further clinical trials especially in Indian children will tell if it stands the test of time.
Related Concept Videos
Extraction: Advanced Methods
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
The Early Endosome: Endocytosis of Transferrin
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
